Veterinary Tuberculosis Vaccine Market Analysis

Bovine Tuberculosis (TB) is an infectious disease of cattle. It is caused by the bacterium Mycobacterium bovis (M. bovis), which can also infect and cause disease in several other mammals including humans, deer, goats, pigs, cats, dogs, and badgers. In cattle, it is mainly a respiratory disease but clinical signs are rare. The prototype vaccination for domestic livestock and wildlife was Bacille Calmette-Guérin (BCG). The Bacillus of Calmette and Guerin (BCG) strain of mycobacterium bovis is used in the BCG vaccine for percutaneous application. It is an attenuated, live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of Mycobacterium bovis. The TICE (Bacillus of Calmette and Guerin) strain, which is used in this BCG vaccine formulation, was created at the University of Illinois from a Pasteur Institute.

Global veterinary tuberculosis vaccine market is estimated to be valued at US$ 50.89 Mn in 2022 and is expected to exhibit a CAGR of 3.2% over the forecast period (2022-2030).

Figure 1: Global Veterinary Tuberculosis Vaccine Market Share (%) Analysis, By Product Type, 2022

Increasing government initiative for veterinary tuberculosis vaccine is expected propel the global veterinary tuberculosis vaccine market growth over the forecast period.

Increasing government initiative for veterinary tuberculosis vaccine is expected propel the global veterinary tuberculosis vaccine market growth over the forecast period. For instance, on July 22, 2020, the Department for Environment, Food & Rural Affairs and Animal and Plant Health Agency, U.K, had given permission to scientists from U.K. government research organization to conduct field trial for bovine tuberculosis (bTB) TB cattle vaccination.  These field trials would be conducted over the next four years from 2021 till 2024 on behalf of Defra, the Welsh Government and the Scottish Government, following of ground-breaking research into bovine TB vaccines and diagnostic tests.

Increasing research and development for tuberculosis vaccine is expected to drive the global veterinary tuberculosis vaccine market growth over the forecast period.

Increasing research and development for tuberculosis vaccine is expected to drive the global veterinary tuberculosis vaccine market growth over the forecast period. For instance, on  November 28, 2019, an article was published by the University of Surrey about the research for new vaccine developed for treating bovine tuberculosis (bovine TB) in form of a novel vaccine and complementary skin test to protect cattle. The scientific study has been published for novel vaccine and complementary skin test to protect cattle. The protective efficiency of the new strain was tested in guinea pigs.

Veterinary Tuberculosis Vaccine Market Report Coverage

Report Coverage	Details
Base Year:	2021	Market Size in 2022:	US$ 50.89 Mn
Historical Data for:	2017 to 2020	Forecast Period:	2022 to 2030
Forecast Period 2022 to 2030 CAGR:	3.2%	2030 Value Projection:	US$ 65.36 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Type: Live Attenuated, Inactivated By Route of Administration: Sub-cutaneous, Intramuscular, Oral By Animal Type: Cattle, Dogs, Cats, Others
Companies covered:	Merck KGaA, Colorado Serum Company, CZ Vaccines (Zendal), and Zoetis Inc.
Growth Drivers:	Increasing government initiatives for veterinary tuberculosis vaccine Increasing research and development for tuberculosis vaccine
Restraints & Challenges:	Discontinuation of animal vaccine

Global Veterinary Tuberculosis Vaccine Market- Impact of the Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it a public health emergency on January 30, 2020.

The COVID-19 can affect the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, the U.A.E., Egypt, and others are facing problems with regard to the transportation of drugs from one place to another.

The current pandemic of COVID-19 has set off an urgent search for an effective vaccine. This search may well benefit from the experiences of the animal health profession in the development and use of coronavirus vaccines in domestic animal species. According to an article published on July 14, 2020 by the National Center for Biotechnology Information (NCBI) stated about new developed vaccine for animal species, where two types of vaccine have been developed against alphacoronaviru (CCoV) such as inactivated and live-attenuated vaccination for dogs with an inactivated CCoV vaccine reduced the level of viral shedding in the feces and was effective following experimental challenge in dogs. Thus, 15% of vaccinated dogs developed mild symptoms while 80% of unvaccinated dogs developed disease symptoms and 60% eventually developed severe symptoms.

Global Veterinary Tuberculosis Vaccine Market– Restraints

Discontinuation of animal vaccine is expected to hamper growth of the global veterinary tuberculosis vaccine market over the forecast period.

For instance, on April 16, 2019, Wisconsin Department of Agriculture announced that Boehringer Ingelheim, an animal healthcare company discontinued Mycopar, a vaccine used in Johne’s disease in herd. Mycopar is currently the only Johne’s vaccine licensed in the U.S. As a result, veterinarians would need to advise herd owners using the vaccine that the product would no longer be one of the tools available to manage Johne’s disease in Wisconsin.

Global Veterinary Tuberculosis Vaccine Market– Regional Analysis

On the basis of region, the Global Veterinary Tuberculosis Vaccine Market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

Among regions, Asia Pacific market is expected to witness significant growth, owing to key companies in market focusing on adopting inorganic strategies such as agreements with other market players. Bovine tuberculosis (bTB) is common is Asia. A significant prevalence of bTB in the region is expected to drive the market growth. For instance, according to an article published in 2018 in Transboundary and Emerging Disease, in 2017, the prevalence of bTB in India was 7.3%.However, according to the World Animal Health Information System, bovine TB is found in most parts of Asia. However, most of the pacific island countries such as Micronesia, New Caledonia, and Papua New Guinea have never reported this disease. In addition, in Australia, bTB has successfully been eradicated from cattle. The last known cases of bTB in Australia were detected in 2002. Several countries such as Japan, Mongolia, Myanmar, Singapore, and Thailand have successfully reduced bovine TB from their cattle population.

Figure 2: Global Veterinary Tuberculosis Vaccine Market Value (US$ Bn), by Region, 2022

Global Veterinary Tuberculosis Vaccine Market– Competitive Landscape

Major players operating in the global veterinary tuberculosis vaccine market include Merck KGaA, Colorado Serum Company, CZ Vaccines (Zendal), and Zoetis Inc.